Replies to post #47 on Myriad Genetics Inc. (MYGN)

[surf1944]

1:33AM Myriad Genetics announces AstraZeneca (AZN) advances PARP inhibitor into Phase 3 Trial With BRACAnalysis (MYGN) 32.10 : Myriad Genetics announces that AstraZeneca (AZN) will use Myriad's BRACAnalysis test as a companion diagnostic to stratify patients in AstraZeneca's pivotal Phase 3 clinical studies for olaparib. Myriad has submitted an Investigational Device Exemption with the FDA for BRACAnalysis testing, which will allow the test to be used as a companion diagnostic to identify potential responders to olaparib therapy in the United States.